Darbepoetin improves endothelial function and increases circulating endothelial progenitor cell number in patients with coronary artery disease

Heart

Volumn 97, Issue 18, 2011, Pages 1474-1478

  Mueller, Cornelius ^a   Wodack, Karin ^a   Twelker, Kaja ^a   Werner, Nikos ^a   Custodis, Florian ^a   Nickenig, Georg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CD133 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; GLYCERYL TRINITRATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; STATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE;

AGED; CORONARY DISEASE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STEM CELLS;

EID: 80052169578     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.220798     Document Type: Article

References (26)

1. Lusis F. Atherosclerosis. Nature 2000;407:233-41.
2. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol 2006;26:257-66. (Pubitemid 43732183)
3. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003;9:1370-6.
4. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004;109:220-6. (Pubitemid 38114143)
5. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53. (Pubitemid 39100452)
6. Wassmann S, Werner N, Czech T, et al. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res 2006;99:e74-83. (Pubitemid 44556373)
7. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007. (Pubitemid 41262334)
8. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6.
9. Foley RN. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 2008;13:405-14.
10. Urao N, Okigaki M, Yamada H, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006;98:1405-13.
11. Noguchi CT, Wang L, Rogers HM, et al. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008;10:e36.
12. Santhanam AV, d'Uscio LV, Peterson TE, et al. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008;29:1451-5.
13. d'Uscio LV, Katusic ZS. Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein Kinase B alpha/Akt1. Hypertension 2008;52:93-9.
14. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114:2850-70.
15. Agarwal AK. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease. Expert Opin Drug Saf 2009;8:145-53.
16. Wauters I., Vansteenkiste J. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 2009;9:221-30.
17. Jelkmann W. Erythropoiesis stimulating agents and techniques: a challenge for doping analysts. Curr Med Chem 2009;16:1236-47.
18. Kang HJ, Kim HS. G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction. Expert Rev Cardiovasc Ther 2008;6:703-13.
19. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-9. (Pubitemid 40228212)
20. Brunner S, Winogradow J, Huber BC, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR4/SDF1 axis. FASEB J 2009;23:351-61.
21. Mihov D, Vogel J, Gassmann M, et al. Erythropoietin activates nitric oxide synthase in murine erythrocytes. Am J Physiol Cell Physiol 2009;297:C378-88.
22. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005;68:299-306. (Pubitemid 41428426)
23. Marzo F, Lavorgna A, Coluzzi G, et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 2008;26:183-7.
24. Cunnington C., Channon K.M. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart 2010;96:1872-7.
25. van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-91. (Pubitemid 38295436)
26. Mills NL, Tura O, Padfield GJ, et al. Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart 2009;95:2003-8.